openPR Logo
Press release

HDAC Inhibitors Market - Future and Technological Advancement 2026

06-16-2018 12:26 PM CET | Health & Medicine

Press release from: Coherent Market Insights

HDAC Inhibitors Market - Future and Technological Advancement

HDAC inhibitors refers to the class of anti-cancer agents that play a vital role in non-epigenetic or epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone deacetylase inhibitors (HDACi) are promising therapeutics, which have already shown potential for oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Vorinostat (Merck & Co. Inc.) is a novel drug used in the management of cutaneous T cell lymphoma during disease progression or relapse or while undergoing treatment. Current candidates are demonstrating successful pre-clinical and clinical trials for various other diseases such as neurological ailments, heart diseases, and HIV infections.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/hdac-inhibitors-market-1294

Numerous classes of Histone deacetylase inhibitors, include benzamides such as MS-275, organic hydroxamic acids such as TSA and SAHA, cyclic tetrapeptides such as sulfonamide anilides and trapoxin, and short-chain fatty acids such as valproic acid and butyrates. Increasing number of applications in different therapeutic areas such as neurodegenerative diseases, including Huntington’s and Alzheimer’s disease, Polycythemia vera, inflammation, and essential Thrombocythemia, Myelofibrosis, is expected to fuel the demand for HDAC inhibitors in the near future.

Increasing R&D activities for cancer is expected to boost HDAC inhibitors market during the forecast period

In February 2015, Novartis received the U.S. FDA approval for Farydak capsules along with dexamethasone and bortezomib*, for patients suffering from multiple myeloma, who previously received minimum two regimens. FDA approval of few HDAC inhibitors for cancer treatment has created interest in finding new products as potential anti-cancer drugs. Moreover, increasing R&D activities for the treatment of cancer and other neurological disorders is one of the prime factors responsible for growth of the HDAC inhibitors market. Around 350 clinical trials were carried out or under process using HDACi as single therapeutic or along with other targeted agents against different human diseases. However, uncertainty issues about the therapeutic potential of HDAC inhibitors and stringent reimbursement policies is expected to impede growth of the market in near future. For instance, there can be significant delays in gaining reimbursement and coverage for newly approved drugs by FDA or other foreign regulatory authorities.

To get holistic SAMPLE of the report: https://www.coherentmarketinsights.com/insight/request-sample/1294

Market Taxonomy

On the basis of application, the HDAC inhibitors market is segmented into:

Oncology
Neurology
Other

On the basis of end user, the HDAC inhibitors market is segmented into:

Hospitals
Oncology Clinics
Other

North America is expected to hold a dominant position in the HDAC inhibitors market due to increasing demand for cancer therapeutics in the region

Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur in the U.S. Better funding for R&D for cancer treatment, and growing demand for efficient treatment with lower costs are other factors driving growth of the market. In 2017, Congress approved the 21st Century Cures Act, sanctioning US$ 1.8 billion in aid for the Cancer Moonshot initiative for 7 years. Europe is expected to foresee tremendous growth during the forecast period (2017–2025), due to growing presence of well-established healthcare infrastructure, early adoption of innovative therapeutics, and growing R&D spending capacity.

Increasing collaborations for R&D among pharmaceutical companies is expected to boost market growth

Major players operating in the HDAC inhibitors market include AbbVie, Celgene, Celldex, Chipscreen, Chroma Therapeutics, GSK, Merck, Novartis, Onxeo, Syndax, and Spectrum Pharmaceuticals. Various pharmaceutical firms are increasingly investing in R&D and preclinical activities of HDACi for different applications. In January 2018, Syndax and Genentech extended their study of the effects of combining PD-L1 and HDAC inhibitors. This new contract permits Genentech to test its Tecentriq with Syndax’s entinostat in a subset of breast cancer patients.

Request Discount on this Report- https://www.coherentmarketinsights.com/insight/request-discount/1294

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: https://globalresearchtrends.blogspot.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HDAC Inhibitors Market - Future and Technological Advancement 2026 here

News-ID: 1085066 • Views: 638

More Releases from Coherent Market Insights

Colostrum Market Grow at a CAGR of 4 % Forecast to 2027 | APS Biogroup, Biostrum …
Colostrum is the first milk produced by newborn humans, cows, and other mammals. It is nutrient-dense and contains antibodies, which are necessary for infants and newborn animals to fight infections and grow normally.The most recent research on the global "Colostrum Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services
Magnesium Oxide Market Grow at 4.16% CAGR Between 2019 and 2027 | Martin Mariett …
Magnesium oxide, also known as magnesia, is a chemical compound with numerous applications.The most recent research on the global "Magnesium Oxide Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services are all included in Magnesium Oxide market research reports. Key statistics on Magnesium Oxide market conditions, size, share, and
Fine Hydrate Market Is Expected To Reach USD 550 million by 2027 | Nabaltec AG, …
Fine hydrate is a non-halogenated flame retardant additive used in injection moulding, wire and cable compounds, and paints and polymers, among other applications.The most recent research on the global "Fine Hydrate Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services are all included in Fine Hydrate market research reports.
GCC Lubricant Packaging Market Growth with 3.3 % CAGR Predicted till 2019-2027 | …
Lubricant packaging is used to store lubricants so that they can maintain their properties for a set period of time.The most recent research on the global "GCC Lubricant Packaging Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services are all included in GCC Lubricant Packaging market research reports. Key

All 5 Releases


More Releases for HDAC

HDAC Inhibitors Market Report 2020: Annual Estimates & Forecasts 2027
The “HDAC Inhibitors Market” Research Report 2020-2027 is a specialized and in-depth study of the HDAC Inhibitors industry with a focus on the global market trend. The report aims to provide an overview of global HDAC Inhibitors Market with detailed market segmentation by component, deployment model, end-user and geography. The global HDAC Inhibitors Market is expected to witness high growth during the forecast period. The report provides key statistics on
HDAC Inhibitors Market - Trends and Opportunities 2017 - 2025
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitor Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Histone Deacetylase (HDAC) Inhibitor Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-histone-deacetylase-hdac-inhibitor-market-research-report-2017-1541214 In this report, the global Histone Deacetylase (HDAC) Inhibitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented